Logo
Knowledge Resource Center/Library

Bad blood : (Record no. 12925)

000 -LEADER
fixed length control field 05123cam a2200469 i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20230325152454.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 180316s2018 nyu b 001 0 eng
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781509868087
040 ## - CATALOGING SOURCE
Transcribing agency AEF
042 ## - AUTHENTICATION CODE
Authentication code pcc
043 ## - GEOGRAPHIC AREA CODE
Geographic area code n-us---
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER
Edition number 23rd ed.
Classification number 338.7/681761
Item number CAR
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Carreyrou, John,
Relator term author.
9 (RLIN) 2805
245 10 - TITLE STATEMENT
Title Bad blood :
Remainder of title secrets and lies in a Silicon Valley startup /
Statement of responsibility, etc. John Carreyrou.
250 ## - EDITION STATEMENT
Edition statement 2nd ed.
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. London:
Name of publisher, distributor, etc. Picador,
Date of publication, distribution, etc. 2019
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture New York :
Name of producer, publisher, distributor, manufacturer Alfred A. Knopf,
Date of production, publication, distribution, manufacture, or copyright notice 2018.
300 ## - PHYSICAL DESCRIPTION
Extent x, 339 pages ;
Dimensions 25 cm
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term unmediated
Media type code n
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term volume
Carrier type code nc
Source rdacarrier
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note Includes bibliographical (pages 305-324) and index.
520 ## - SUMMARY, ETC.
Summary, etc. "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Assigning source Provided by publisher.
520 ## - SUMMARY, ETC.
Summary, etc. "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Assigning source Provided by publisher.
610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element Theranos (Firm)
General subdivision History.
9 (RLIN) 2806
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hematologic equipment industry
Geographic subdivision United States.
9 (RLIN) 2807
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Fraud
Geographic subdivision United States.
9 (RLIN) 2808
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element BUSINESS & ECONOMICS / Entrepreneurship.
Source of heading or term bisacsh
9 (RLIN) 2809
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element BUSINESS & ECONOMICS / Finance.
Source of heading or term bisacsh
9 (RLIN) 2810
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element TECHNOLOGY & ENGINEERING / Biomedical.
Source of heading or term bisacsh
9 (RLIN) 2811
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Koha item type Book
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent Location Current Location Date acquired Source of acquisition Cost, normal purchase price Barcode Date last seen Cost, replacement price Price effective from Koha item type
          AEF's Arihant college of Arts, Commerce and Science, Camp, Pune-01 AEF's Arihant college of Arts, Commerce and Science, Camp, Pune-01 2023-04-11 20 374.25 8356 2023-04-11 499.00 2023-04-11 Book
AEF's, Arihant College of Arts, Commerce and Science, Camp, Pune-01 . All Rights Reserved.
Implemented by Sheetal Ankushe

Powered by Koha